Related Experiment Video
Updated: Jun 10, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Glucagon-like peptide 1--a cardiologic dimension
Marek Treiman1, Mikkel Elvekjaer, Thomas Engstrøm
1Department of Biomedical Sciences and The Danish National Foundation Research Center for Heart Arrhythmia, University of Copenhagen, Copenhagen, Denmark. m.treiman@mfi.ku.dk
Trends in Cardiovascular Medicine
|August 6, 2010
Summary
Glucagon-like peptide 1 (GLP-1) shows direct cardiovascular benefits, including heart protection and improved function. Further clinical trials are needed to confirm its potential in treating heart conditions like myocardial infarction.
Area of Science:
- Cardiovascular Science
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide 1 (GLP-1) is known for its glucose-regulating effects.
- Emerging evidence suggests GLP-1 and its analogs exert direct cardiovascular actions.
- These actions may include cardioprotection, enhanced contractility, and vasodilation.
Purpose of the Study:
- To review the direct cardiovascular effects of GLP-1 and its analogs.
- To explore the potential therapeutic applications of GLP-1 in cardiovascular diseases.
- To highlight promising areas for future clinical investigation.
Main Methods:
- Review of recent experimental data and preliminary clinical trials.
- Analysis of findings from animal studies on post-ischemic myocardial injury.
- Synthesis of evidence regarding GLP-1's impact on cardiac function and structure.
Main Results:
- GLP-1 demonstrates potential cardioprotective, contractility-augmenting, and vasorelaxant properties.
- Preliminary clinical data suggest mechanical function improvement in patients with left ventricular dysfunction.
- Animal studies indicate reduced myocardial injury following ischemia-reperfusion.
Conclusions:
- GLP-1 and its analogs possess direct cardiovascular effects beyond their metabolic actions.
- These agents show promise for improving cardiac mechanical function and reducing ischemic injury.
- Further clinical trials are warranted to validate these findings and explore therapeutic potential.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...